The Psychedelics Newsletter

Beckley Psytech’s CEO Cosmo Feilding Mellen on raising US$80 million; Awakn Life Sciences begins trading on OTCQB; atai Life Sciences creates subsidiary for salvia divinorum derivatives. Read more in Issue 42 of the Psychedelics Newsletter.

Overwhelming majority of Canadians support legalisation of psilocybin; Could psychedelic drugs revolutionise mental healthcare in the UK? Cybin becomes first psychedelic company to list on the New York Stock Exchange. Read more in Issue 41 of the Psychedelics Newsletter

BHMNC Brain Health on precision psychiatry and psychedelics; Global psychedelics research institute launched in Melbourne with AU$40m in funding; Poll reveals majority of Canadians support legalisation of psilocybin-assisted therapy. Read more in Issue 40 of the Psychedelics Newsletter

Field Trip’s Co-founder and Executive Chairman Ronan Levy on investor opportunities following Nasdaq listing; Cybin to list on NYSE’s Small Cap Market to finance expansion; The Times: Psychedelic firms take a trip over the Atlantic in search of funds. Read more in Issue 39 of the Psychedelics Newsletter.

Biden calls for lower drug prices: should psychedelics investors be concerned? Jamaica adopts protocols for cultivating and possessing psilocybin; Nasdaq explores the growth of the psychedelic industry. Read more in Issue 38 of the Psychedelics Newsletter

Data science driving innovation in psychedelic medicine; Looking back on the PSYCH Investor Summit: Research & Development; atai Life Sciences’ Founder warns decriminalisation could set back regulation. Read more in Issue 37 of the Psychedelics Newsletter.

PSYCH Investor Summit: Research & Development kicks off today; Tryp Therapeutics to treat psychiatric disorders; Braxia Scientific identifies short-term ROI in psychedelic medicine. Read more in Issue 36 of the Psychedelics Newsletter.

One week remains until the PSYCH Investor Summit: Research & Development; Texas legalises medical psychedelic research; Compass Pathways conducts world’s largest psilocybin trial to-date. Read more in Issue 35 of The Psychedelics Newsletter.

Awakn Life Sciences lists on the NEO Exchange; examining psychedelic revenue opportunities within tight regulations; IPOs build momentum as atai Life Sciences goes public. Read more in Issue 34 of The Psychedelics Newsletter.

Examining the business impact of North American psychedelic drug regulations; atai Life Sciences targets US$2.3 billion IPO valuation; and democrats introduce a bill to end the War on Drugs. Read more in Issue 33 of The Psychedelics Newsletter.

Three new speakers for the PSYCH Investor Summit; MindMed CEO steps down; study begins on psychedelics as a treatment for COVID distress. Read more in Issue 32 of The Psychedelics Newsletter.

For-profit or non-profit? That is the ($100-billion) question. Rick Doblin and Christian Angermayer join the 7 July PSYCH Investor Summit: Research and Development to discuss the role of non and for-profit businesses in a can’t-miss conversation. Read more in Issue 31 of The Psychedelics Newsletter.